


4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline

Chemical Properties

CAS No. :	183322-18-1
Formula:	C ₁₄ H ₁₇ ClN ₂ O ₄
Molecular Weight:	312.75
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate. It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds. It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib, with antiproliferative activity.
Targets(IC50)	Others

Solubility Information

Solubility	DMSO: 10 mg/mL (31.97 mM), Sonication is recommended. Ethanol: 1 mg/mL (3.2 mM), Sonication is recommended. DMF: PBS (pH 7.2) (1:4): 0.2 mg/mL (0.64 mM), Sonication is recommended. DMF: 30 mg/mL (95.92 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1974 mL	15.9872 mL	31.9744 mL
5 mM	0.6395 mL	3.1974 mL	6.3949 mL
10 mM	0.3197 mL	1.5987 mL	3.1974 mL
50 mM	0.0639 mL	0.3197 mL	0.6395 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Pandey, A., Volkots, D.L., Seroogy, J.M., et al. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. *Med. Chem.* 45(17)3772-3793(2002)
- Li, W.W., Wang, X.Y., Zheng, R.L., et al. Discovery of the novel potent and selective FLT3 inhibitor 1-[5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl]-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo. *Med. Chem.* 55(8)3852-3866(2012)
- Zhang, X., Su, M., Chen, Y., et al. The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. *Molecules* 18(6)6491-6503(2013)
- Liu, Z., Wang, L., Feng, M., et al. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers. *Bioorg. Chem.* 77593-599(2018)
- Knesl, P., R?seling, D., and Jordis, U. Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinib. *Molecules* 11(4)286-297(2006)

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481